Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 39 recruiting now full pipeline #105 of 28,707 conditions

Diabetes Mellitus, Type 1: full-pipeline trial registry

39 of 119 indexed Diabetes Mellitus, Type 1 trials are currently recruiting.

Corpus placement: #105 of 28,707 conditions by registered trial count.

119 US clinical trials · 39 currently recruiting · #105 of 28,707 conditions by registered trial count

Diabetes Mellitus, Type 1: 119 US clinical trials tracked, 39 recruiting.

Diabetes Mellitus, Type 1 is the subject of 119 registered US clinical trials on ClinicalTrials.gov, 39 of them currently open to new participants. 31 are in Phase 3-4 (later-stage) and 27 in Phase 1-2 (earlier-stage). The most active sponsor is Novo Nordisk A/S, running 11 of these trials.

Enrollment posture brief

Registry condition diabetes-mellitus-type-1

OPEN 39 | RECR 33% | LATE 31 | EARLY 27 | RANK #105 | SPON 11

Nearest open-share peer: Non-alcoholic Fatty Liver Disease (33% recruiting · 58 trials)

Triple Negative Breast Cance57.1%Healthy Participants35%Postoperative Pain34.7%Diabetes Mellitus, Type (th…33%Weight Loss26.1%
Open-enrollment share among volume-matched conditions near Diabetes Mellitus, Type 1

Diabetes Mellitus, Type 1 lists 39 open slots (33% of 119 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Diabetes Mellitus, Type 1 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Diabetes Mellitus, Type 1 is recruiting below its size-band peers.

    39 of 119 indexed trials (32.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Diabetes Mellitus, Type 1 trials is spread across many organizations.

    Novo Nordisk A/S accounts for 11 of 119 trials (9.2%). 70 distinct sponsors appear on at least one study for this condition label.

  3. Typical Diabetes Mellitus, Type 1 enrolment sits around 73 participants.

    Median target enrolment is 73 among the 119 trials that report a genuine target (sentinel values excluded). 70 of those (58.8%) plan for fewer than 100 participants.

  4. Diabetes Mellitus, Type 1 research is mostly interventional.

    105 interventional and 14 observational studies make up this index (88.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 113Phase 214Phase 323Phase 48

Open and recent trials

119 total, page 3 of 3

COMPLETED NA 29 participants

A Pilot Study of Biomarkers of Stress in Youth Who Use Teens.Connect

Yale University

NCT02970656

COMPLETED Phase 2 29 participants

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

Mannkind Corporation

NCT00662857

COMPLETED NA 27 participants

A Continuous Glucose Monitor Based Insulin Bolus Calculator

Welldoc

NCT05229445

COMPLETED Phase 4 25 participants

Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.

Sansum Diabetes Research Institute

NCT03668808

COMPLETED 22 participants

Study of Calcium Metabolism in Teenage Girls With Type 1 Diabetes

University of Rochester

NCT03156179

COMPLETED NA 21 participants

Assessment of an Automatic Closed-loop Insulin Delivery System

Stanford University

NCT02366767

COMPLETED Phase 4 20 participants

Afrezza® Dosing Optimization Study

Mannkind Corporation

NCT04849845

COMPLETED Phase 2 20 participants

To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.

Pfizer

NCT00143104

COMPLETED Phase 2 18 participants

Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D

Xeris Pharmaceuticals

NCT04074317

COMPLETED NA 14 participants

A Clinical Study to Investigate and Compare the Impact of High Protein Pasta, Lower Protein Pasta and White Rice on Blood Sugar Control in People With Type 1 Diabetes Mellitus (T1DM)

Sansum Diabetes Research Institute

NCT03362151

COMPLETED NA 12 participants

Effect of Medium Chain Fatty Acids on Cognitive Function During Acute Hypoglycemia in Patients With Type 1 Diabetes

Yale University

NCT00592072

COMPLETED Phase 2 10 participants

A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus

GlaxoSmithKline

NCT00575159

COMPLETED Phase 1 10 participants

Islet Transplantation for Patients With Type 1 Diabetes

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00073281

COMPLETED NA 10 participants

Acceptability of Virtual Educational Intervention for Adolescents and Young Adults With Type 1 Diabetes Mellitus

University Hospitals Cleveland Medical Center

NCT04878419

COMPLETED NA 9 participants

Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus

University of Virginia

NCT01839370

COMPLETED NA 9 participants

Integrated Behavioral Healthcare for Youth With Type 1 Diabetes

University of Miami

NCT05915975

COMPLETED Phase 4 8 participants

Sitagliptin Dose Determination Study

Albert Einstein College of Medicine

NCT01530178

COMPLETED Phase 2 7 participants

Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation

Rodolfo Alejandro

NCT00315588

COMPLETED NA 7 participants

Pharmacokinetics (PK)/ Pharmacodynamics (PD) of an Extended Wear Infusion Set for Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 Diabetes Mellitus (T1DM) Patients ("PEXIS")

Capillary Biomedical

NCT04398030

← Previous Page 3 of 3

Phase Distribution

PhaseTrial count
Phase 1 13
Phase 2 14
Phase 3 23
Phase 4 8

Named interventions

Most-linked intervention names on Diabetes Mellitus, Type 1 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
9 trials
insulin aspart Drug
7 trials
Insulin Lispro Drug
3 trials
insulin degludec Drug
3 trials
Insulin Glargine Drug
3 trials
Intraportal infusion of islet cells Procedure
3 trials
Human Insulin Inhalation Powder Drug
2 trials
Faster-acting insulin aspart Drug
2 trials

US sites by state

Facility locations filed on Diabetes Mellitus, Type 1 trials. A trial with sites in several states counts in each.

California 56 trials
Florida 39 trials
Colorado 34 trials
Georgia 24 trials
New York 21 trials
Illinois 20 trials
Texas 18 trials
Pennsylvania 17 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Diabetes Mellitus, Type 1 page

119 registered trials, 39 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 39 Diabetes Mellitus, Type 1 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Novo Nordisk A/S sponsors the most Diabetes Mellitus, Type 1 trials on record, review their full trial history before evaluating a specific study. See Novo Nordisk A/S's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetes Mellitus, Type 1 condition card totals 119 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.